<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01830881</url>
  </required_header>
  <id_info>
    <org_study_id>OHSU IRB 9064</org_study_id>
    <nct_id>NCT01830881</nct_id>
  </id_info>
  <brief_title>Evaluation of Oral Midazolam in First-trimester Surgical Abortions</brief_title>
  <official_title>An Evaluation of Oral Midazolam for Anxiety and Pain in First-trimester Surgical Abortion: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the level of pain, anxiety and side effects that
      women experience with a surgical abortion and the effect that the anti-anxiety medication,
      midazolam, might have when used along with ibuprofen and a paracervical block (PCB) instead
      of the standard pain treatment of only ibuprofen and a PCB.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Women in the study will be randomized to receive either midazolam or placebo. Every
      participant will still receive the standard oral medications for pain (ibuprofen) as well as
      an injection of numbing medicine (lidocaine) near the cervix (PCB). The co-primary outcomes
      are patient perception of anxiety and pain with uterine aspiration reported on a 100 mm
      visual analogue scale (VAS). Secondary outcomes include reported anxiety and pain at time
      points before, during, and after the procedure, as well as subject satisfaction with anxiety
      and pain control and overall abortion experience. Due to the dose-dependent anterograde
      amnesic effect of midazolam, we will also investigate the effects on memory and recall, which
      has not previously been studied. In addition, we will also collect data on side effects
      frequently associated with oral midazolam such as nausea and sleepiness. Women will also be
      responsible for completing a one-page survey 1-3 days after the procedure visit and return it
      by mail using a pre-addressed and stamped envelope.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subject Perception of Pain and Anxiety During Uterine Aspiration</measure>
    <time_frame>at time of uterine aspiration (30-60 minutes after premedication)</time_frame>
    <description>Subjects will be asked to rate anxiety and pain at the time of uterine aspiration by marking along a 100 mm Visual Analog Scale, with 0mm being No Pain/Anxiety and 100mm being Worst Imaginable Pain/Anxiety</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subject Anticipated Perception of Pain and Anxiety During Uterine Aspiration at Baseline</measure>
    <time_frame>Baseline (upon entry into study)</time_frame>
    <description>Subjects will be asked to rate their anticipated anxiety and pain at the time of uterine aspiration by marking along a mm Visual Analog Scale, with 0mm being No Pain/Anxiety and 100mm being Worst Imaginable Pain/Anxiety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Perception of Pain and Anxiety Upon Entering Procedure Room</measure>
    <time_frame>upon entering procedure room (30-60 minutes after premedication)</time_frame>
    <description>Subjects will be asked to rate anxiety and pain upon entering procedure room by marking along a mm Visual Analog Scale, with 0mm being No Pain/Anxiety and 100mm being Worst Imaginable Pain/Anxiety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Perception of Pain and Anxiety Post Procedure</measure>
    <time_frame>30 minutes post operatively</time_frame>
    <description>Subjects will be asked to rate anxiety and pain 30 minutes post-operatively by marking along a mm Visual Analog Scale, with 0mm being No Pain/Anxiety and 100mm being Worst Imaginable Pain/Anxiety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Perception of Anxiety With Patient Positioning Procedure</measure>
    <time_frame>prior to starting pelvic exam (30-60 minutes after premedication)</time_frame>
    <description>Subjects will be asked to rate anxiety prior to starting pelvic exam by marking along a mm Visual Analog Scale, with 0mm being No Anxiety and 100mm being Worst Imaginable Anxiety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Perception of Pain During Cervical Dilation</measure>
    <time_frame>with cervical dilation (30-60 minutes after premedication)</time_frame>
    <description>Subjects will be asked to rate pain at the time of cervical dilation by marking along a mm Visual Analog Scale, with 0mm being No Pain and 100mm being Worst Imaginable Pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation Coefficient Between State-Trait Anxiety Inventory Form Y-1 and Visual Analog Scale for Anxiety at Baseline</measure>
    <time_frame>Baseline (upon entry into study)</time_frame>
    <description>To measure the Correlation coefficient between the State-Trait Anxiety Inventory (STAI) Form Y-1 and Visual Analog Scale for anxiety.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction With Pain and Anxiety 30 Minutes Postoperatively</measure>
    <time_frame>30 minutes post-operatively</time_frame>
    <description>To assess whether oral midazolam is associated with differences in overall patient satisfaction with pain and anxiety control and abortion experience at 30 min postoperatively as measured by a mm Visual Analog Scale with 0mm being Not At All Satisfied and 100mm being Very Satisfied</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Satisfaction With Pain and Anxiety 1-3 Days Post Procedure</measure>
    <time_frame>1-3 days post-operatively</time_frame>
    <description>To assess whether oral midazolam is associated with differences in overall patient satisfaction with pain and anxiety control and abortion experience at 1-3 days postoperatively as measured by a mm VAS with 0mm being Not At All Satisfied and 100mm being Very Satisfied</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Extent of Amnesia Using Amnesia Score</measure>
    <time_frame>30 minutes postoperatively</time_frame>
    <description>To assess the extent of amnesia 30 min postoperatively as measured by ability to recall procedure using 4-point scale (0 = unable to recall any proportion of the procedure, 1 = able to recall and describe some portions of the procedure, but overall has minimal recall of the procedure, 2 = able to recall and describe most of the procedure, but admits to inability to recall some portion of the procedure, 3 = able to recall and describe the entire procedure).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Extent of Amnesia</measure>
    <time_frame>1-3 days postoperatively</time_frame>
    <description>To assess the extent of amnesia 1-3 days postoperatively as measured by 100mm Visual Analog Scale with 0mm being Remember Nothing and 100mm being Remember Everything.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Extent of Sedation</measure>
    <time_frame>3-60 minutes after premedication</time_frame>
    <description>Subject extent of sedation 30-60 minutes after premedication, just prior to procedure as measured by the 6-point Ramsay Scale (1 = patient anxious agitated, or restless; 2 = patient cooperative, oriented, and tranquil; 3 = patient asleep, responds to commands only; 4 = patient asleep, responds to gentle shaking, light glabellar tap, or loud auditory stimulus; 5 = patient asleep, responds to noxious stimuli such as firm nail bed pressure; 6 = patient asleep, has no response to firm nail bed pressure or other noxious stimuli)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Vital Signs (Heart Rate)</measure>
    <time_frame>intraoperatively (30-60 minutes after premedication)</time_frame>
    <description>Subject heart rate will be assessed for the duration of the procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Vital Signs (Heart Rate) 30 Minutes Postprocedure</measure>
    <time_frame>30 minutes postoperatively</time_frame>
    <description>Subject vital signs (heart rate) will be assessed 30 minutes postoperatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Nausea 30 Minutes Postprocedure</measure>
    <time_frame>30 minutes postoperatively</time_frame>
    <description>Subject nausea will be assessed 30 minutes postoperatively using a 100mm Visual Analog Scale with 0mm being None and 100mm being Worst Imaginable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Need for Additional Pain Medication</measure>
    <time_frame>intraoperatively and postoperatively (0-120 minutes after premedication)</time_frame>
    <description>Subjects will be assessed for need of additional pain medications during the procedure and postoperatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject's Correct Identification of Receiving Midazolam or Placebo</measure>
    <time_frame>30 minutes postoperatively</time_frame>
    <description>Number of patient's who could correctly determine if they received study drug or placebo when asked</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Vital Signs (Oxygenation Saturation)</measure>
    <time_frame>intraoperatively (30-60 minutes after premedication)</time_frame>
    <description>Subject oxygenation status will be assessed for the duration of the procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Vital Signs (Oxygenation Saturation) 30 Minutes Postprocedure</measure>
    <time_frame>30 minutes postoperatively</time_frame>
    <description>Subject vital signs (oxygenation saturation) will be assessed 30 minutes postoperatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Sleepiness 30 Minutes Postprocedure</measure>
    <time_frame>30 minutes postoperatively</time_frame>
    <description>Subject sleepiness will be assessed 30 minutes postoperatively using a 100mm Visual Analog Scale with 0mm being None and 100mm being Worst Imaginable</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">124</enrollment>
  <condition>Pain</condition>
  <condition>Anxiety</condition>
  <condition>Nausea</condition>
  <arm_group>
    <arm_group_label>placebo-cherry syrup and ibuprofen</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>5 mL oral placebo-cherry syrup and 800 mg oral ibuprofen 30-60 minutes prior to procedure 20 mL injection 1% lidocaine without epinephrine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Midazolam and ibuprofen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5 mL oral midazolam oral syrup (2 mg/mL) and 800 mg oral ibuprofen 30-60 minutes prior to procedure 20 mL injection 1% lidocaine without epinephrine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>5 mL oral midazolam oral syrup (2 mg/mL) 30-60 minutes prior to procedure</description>
    <arm_group_label>Midazolam and ibuprofen</arm_group_label>
    <other_name>Versed</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen</intervention_name>
    <description>800 mg oral ibuprofen 30-60 minutes prior to procedure</description>
    <arm_group_label>placebo-cherry syrup and ibuprofen</arm_group_label>
    <arm_group_label>Midazolam and ibuprofen</arm_group_label>
    <other_name>Motrin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo-Cherry syrup</intervention_name>
    <description>5 mL oral placebo-cherry syrup 30-60 minutes prior to procedure</description>
    <arm_group_label>placebo-cherry syrup and ibuprofen</arm_group_label>
    <other_name>placebo cherry syrup</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine</intervention_name>
    <description>injection of 20 mL 1% lidocaine without epinephrine</description>
    <arm_group_label>placebo-cherry syrup and ibuprofen</arm_group_label>
    <arm_group_label>Midazolam and ibuprofen</arm_group_label>
    <other_name>lidocaine injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 18 years or older

          -  Voluntarily requesting surgical pregnancy termination

          -  Pregnancy with intrauterine gestational sac between 6 0/7 and 10 6/7 weeks gestation,
             dated by ultrasound

          -  Eligible for suction aspiration

          -  English or Spanish speaking

          -  Good general health

          -  Able and willing to give informed consent and agree to terms of the study

          -  Have assistance home; no driving for 24 hours

        Exclusion Criteria:

          -  - Gestational ages 11 0/7 weeks or more

          -  Gestational age less than 6 0/7 weeks

          -  Incomplete abortion

          -  Premedication with misoprostol

          -  Use of narcotic pain or anti-anxiety medication within past 24 hours

          -  Use of heroin or methadone within last 3 months

          -  Chronic alcoholism or alcohol intoxication within past 24 hours

          -  Requested narcotics or Intravenous sedation (prior to randomization)

          -  Allergic reaction or allergy to cherry/cherry flavoring or lidocaine or non-steroidal
             anti-inflammatory drugs (NSAIDs)

          -  Allergic reaction or sensitivity to benzodiazepines including hyperactive or
             aggressive behavior (paradoxical reaction)

          -  Medical problem necessitating inpatient procedure

          -  Untreated acute cervicitis or pelvic inflammatory disease

          -  Known acute narrow-angle glaucoma

          -  Weighing less than 100 lb (45 kg)

          -  Use of potent medications interfering with microsomal metabolism within past 48 hours
             (carbamazepine (Tegretol), cimetidine (Tagamet), diltiazem (Cardizem), erythromycin,
             fluconazole (Diflucan), itraconazole (Sporanox), ketoconazole (Nizoral),
             phenobarbital, phenytoin (Dilantin), nelfinavir, ranitidine (Zantac), rifampin
             (Rifadin), ritonavir (Norvir), saquinavir, verapamil (Calan))
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisa Bayer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Planned Parenthood Columbia Willamette</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 3, 2013</study_first_submitted>
  <study_first_submitted_qc>April 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2013</study_first_posted>
  <results_first_submitted>April 21, 2016</results_first_submitted>
  <results_first_submitted_qc>May 16, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 14, 2017</results_first_posted>
  <last_update_submitted>May 16, 2017</last_update_submitted>
  <last_update_submitted_qc>May 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Lisa Bayer, MD MPH</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>pain</keyword>
  <keyword>anxiety</keyword>
  <keyword>surgical abortion</keyword>
  <keyword>midazolam</keyword>
  <keyword>benzodiazepine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Epinephrine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This randomized, double-blind, placebo-controlled trial was conducted at Planned Parenthood Columbia/ Willamette in Portland, Oregon, between May 2013 and December 2013.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Midazolam and Ibuprofen</title>
          <description>5 mL oral midazolam oral syrup (2 mg/mL) and 800 mg oral ibuprofen 30-60 minutes prior to procedure 20 mL injection 1% lidocaine without epinephrine
Midazolam: 5 mL oral midazolam oral syrup (2 mg/mL) 30-60 minutes prior to procedure
Ibuprofen: 800 mg oral ibuprofen 30-60 minutes prior to procedure
Lidocaine: injection of 20 mL 1% lidocaine without epinephrine</description>
        </group>
        <group group_id="P2">
          <title>Placebo-cherry Syrup and Ibuprofen</title>
          <description>5 mL oral placebo-cherry syrup and 800 mg oral ibuprofen 30-60 minutes prior to procedure 20 mL injection 1% lidocaine without epinephrine
Ibuprofen: 800 mg oral ibuprofen 30-60 minutes prior to procedure
Placebo-Cherry syrup: 5 mL oral placebo-cherry syrup 30-60 minutes prior to procedure
Lidocaine: injection of 20 mL 1% lidocaine without epinephrine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
                <participants group_id="P2" count="62"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
                <participants group_id="P2" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Changed decision to have an abortion</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>1 subject in the placebo group did not complete the study after changing mind to have abortion. Baseline information and characteristics on that subject was still collected and included where applicable in study outcomes and data.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo-cherry Syrup and Ibuprofen</title>
          <description>5 mL oral placebo-cherry syrup and 800 mg oral ibuprofen 30-60 minutes prior to procedure 20 mL injection 1% lidocaine without epinephrine
Ibuprofen: 800 mg oral ibuprofen 30-60 minutes prior to procedure
Placebo-Cherry syrup: 5 mL oral placebo-cherry syrup 30-60 minutes prior to procedure
Lidocaine: injection of 20 mL 1% lidocaine without epinephrine</description>
        </group>
        <group group_id="B2">
          <title>Midazolam and Ibuprofen</title>
          <description>5 mL oral midazolam oral syrup (2 mg/mL) and 800 mg oral ibuprofen 30-60 minutes prior to procedure 20 mL injection 1% lidocaine without epinephrine
Midazolam: 5 mL oral midazolam oral syrup (2 mg/mL) 30-60 minutes prior to procedure
Ibuprofen: 800 mg oral ibuprofen 30-60 minutes prior to procedure
Lidocaine: injection of 20 mL 1% lidocaine without epinephrine</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="62"/>
            <count group_id="B2" value="62"/>
            <count group_id="B3" value="124"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.8" spread="5.3"/>
                    <measurement group_id="B2" value="25.5" spread="5.8"/>
                    <measurement group_id="B3" value="25.6" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="124"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="107"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="86"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Parity</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Nulliparous</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parous</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous vaginal deliveries</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous surgical abortion</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Level of menstrual symptoms</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Easy or mild cramping</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Requiring medication or unable to attend work</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.9" spread="6.0"/>
                    <measurement group_id="B2" value="25.9" spread="5.5"/>
                    <measurement group_id="B3" value="25.9" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Self-reported depression</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Self-reported anxiety</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Subject Perception of Pain and Anxiety During Uterine Aspiration</title>
        <description>Subjects will be asked to rate anxiety and pain at the time of uterine aspiration by marking along a 100 mm Visual Analog Scale, with 0mm being No Pain/Anxiety and 100mm being Worst Imaginable Pain/Anxiety</description>
        <time_frame>at time of uterine aspiration (30-60 minutes after premedication)</time_frame>
        <population>1 subject in the placebo group did not complete the study after changing mind to have abortion. Baseline information and characteristics on that subject was still collected and included where applicable in study outcomes and data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo-cherry Syrup and Ibuprofen</title>
            <description>5 mL oral placebo-cherry syrup and 800 mg oral ibuprofen 30-60 minutes prior to procedure 20 mL injection 1% lidocaine without epinephrine
Ibuprofen: 800 mg oral ibuprofen 30-60 minutes prior to procedure
Placebo-Cherry syrup: 5 mL oral placebo-cherry syrup 30-60 minutes prior to procedure
Lidocaine: injection of 20 mL 1% lidocaine without epinephrine</description>
          </group>
          <group group_id="O2">
            <title>Midazolam and Ibuprofen</title>
            <description>5 mL oral midazolam oral syrup (2 mg/mL) and 800 mg oral ibuprofen 30-60 minutes prior to procedure 20 mL injection 1% lidocaine without epinephrine
Midazolam: 5 mL oral midazolam oral syrup (2 mg/mL) 30-60 minutes prior to procedure
Ibuprofen: 800 mg oral ibuprofen 30-60 minutes prior to procedure
Lidocaine: injection of 20 mL 1% lidocaine without epinephrine</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Perception of Pain and Anxiety During Uterine Aspiration</title>
          <description>Subjects will be asked to rate anxiety and pain at the time of uterine aspiration by marking along a 100 mm Visual Analog Scale, with 0mm being No Pain/Anxiety and 100mm being Worst Imaginable Pain/Anxiety</description>
          <population>1 subject in the placebo group did not complete the study after changing mind to have abortion. Baseline information and characteristics on that subject was still collected and included where applicable in study outcomes and data.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain with Aspiration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.3" spread="20.6"/>
                    <measurement group_id="O2" value="70.1" spread="22.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxiety with Aspiration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.2" spread="28.1"/>
                    <measurement group_id="O2" value="60.9" spread="27.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Anticipated Perception of Pain and Anxiety During Uterine Aspiration at Baseline</title>
        <description>Subjects will be asked to rate their anticipated anxiety and pain at the time of uterine aspiration by marking along a mm Visual Analog Scale, with 0mm being No Pain/Anxiety and 100mm being Worst Imaginable Pain/Anxiety</description>
        <time_frame>Baseline (upon entry into study)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo-cherry Syrup and Ibuprofen</title>
            <description>5 mL oral placebo-cherry syrup and 800 mg oral ibuprofen 30-60 minutes prior to procedure 20 mL injection 1% lidocaine without epinephrine
Ibuprofen: 800 mg oral ibuprofen 30-60 minutes prior to procedure
Placebo-Cherry syrup: 5 mL oral placebo-cherry syrup 30-60 minutes prior to procedure
Lidocaine: injection of 20 mL 1% lidocaine without epinephrine</description>
          </group>
          <group group_id="O2">
            <title>Midazolam and Ibuprofen</title>
            <description>5 mL oral midazolam oral syrup (2 mg/mL) and 800 mg oral ibuprofen 30-60 minutes prior to procedure 20 mL injection 1% lidocaine without epinephrine
Midazolam: 5 mL oral midazolam oral syrup (2 mg/mL) 30-60 minutes prior to procedure
Ibuprofen: 800 mg oral ibuprofen 30-60 minutes prior to procedure
Lidocaine: injection of 20 mL 1% lidocaine without epinephrine</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Anticipated Perception of Pain and Anxiety During Uterine Aspiration at Baseline</title>
          <description>Subjects will be asked to rate their anticipated anxiety and pain at the time of uterine aspiration by marking along a mm Visual Analog Scale, with 0mm being No Pain/Anxiety and 100mm being Worst Imaginable Pain/Anxiety</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Expected Anxiety</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.5" spread="20.6"/>
                    <measurement group_id="O2" value="74.2" spread="20.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Expected Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.2" spread="19.7"/>
                    <measurement group_id="O2" value="69.2" spread="17.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Perception of Pain and Anxiety Upon Entering Procedure Room</title>
        <description>Subjects will be asked to rate anxiety and pain upon entering procedure room by marking along a mm Visual Analog Scale, with 0mm being No Pain/Anxiety and 100mm being Worst Imaginable Pain/Anxiety</description>
        <time_frame>upon entering procedure room (30-60 minutes after premedication)</time_frame>
        <population>1 subject in the placebo group did not complete the study after changing mind to have abortion. Baseline information and characteristics on that subject was still collected and included where applicable in study outcomes and data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo-cherry Syrup and Ibuprofen</title>
            <description>5 mL oral placebo-cherry syrup and 800 mg oral ibuprofen 30-60 minutes prior to procedure 20 mL injection 1% lidocaine without epinephrine
Ibuprofen: 800 mg oral ibuprofen 30-60 minutes prior to procedure
Placebo-Cherry syrup: 5 mL oral placebo-cherry syrup 30-60 minutes prior to procedure
Lidocaine: injection of 20 mL 1% lidocaine without epinephrine</description>
          </group>
          <group group_id="O2">
            <title>Midazolam and Ibuprofen</title>
            <description>5 mL oral midazolam oral syrup (2 mg/mL) and 800 mg oral ibuprofen 30-60 minutes prior to procedure 20 mL injection 1% lidocaine without epinephrine
Midazolam: 5 mL oral midazolam oral syrup (2 mg/mL) 30-60 minutes prior to procedure
Ibuprofen: 800 mg oral ibuprofen 30-60 minutes prior to procedure
Lidocaine: injection of 20 mL 1% lidocaine without epinephrine</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Perception of Pain and Anxiety Upon Entering Procedure Room</title>
          <description>Subjects will be asked to rate anxiety and pain upon entering procedure room by marking along a mm Visual Analog Scale, with 0mm being No Pain/Anxiety and 100mm being Worst Imaginable Pain/Anxiety</description>
          <population>1 subject in the placebo group did not complete the study after changing mind to have abortion. Baseline information and characteristics on that subject was still collected and included where applicable in study outcomes and data.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anxiety at Room Entry</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.4" spread="25.4"/>
                    <measurement group_id="O2" value="34.5" spread="22.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain at Room Entry</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.5" spread="21.1"/>
                    <measurement group_id="O2" value="10.1" spread="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Perception of Pain and Anxiety Post Procedure</title>
        <description>Subjects will be asked to rate anxiety and pain 30 minutes post-operatively by marking along a mm Visual Analog Scale, with 0mm being No Pain/Anxiety and 100mm being Worst Imaginable Pain/Anxiety</description>
        <time_frame>30 minutes post operatively</time_frame>
        <population>1 subject in the placebo group did not complete the study after changing mind to have abortion. Baseline information and characteristics on that subject was still collected and included where applicable in study outcomes and data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo-cherry Syrup and Ibuprofen</title>
            <description>5 mL oral placebo-cherry syrup and 800 mg oral ibuprofen 30-60 minutes prior to procedure 20 mL injection 1% lidocaine without epinephrine
Ibuprofen: 800 mg oral ibuprofen 30-60 minutes prior to procedure
Placebo-Cherry syrup: 5 mL oral placebo-cherry syrup 30-60 minutes prior to procedure
Lidocaine: injection of 20 mL 1% lidocaine without epinephrine</description>
          </group>
          <group group_id="O2">
            <title>Midazolam and Ibuprofen</title>
            <description>5 mL oral midazolam oral syrup (2 mg/mL) and 800 mg oral ibuprofen 30-60 minutes prior to procedure 20 mL injection 1% lidocaine without epinephrine
Midazolam: 5 mL oral midazolam oral syrup (2 mg/mL) 30-60 minutes prior to procedure
Ibuprofen: 800 mg oral ibuprofen 30-60 minutes prior to procedure
Lidocaine: injection of 20 mL 1% lidocaine without epinephrine</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Perception of Pain and Anxiety Post Procedure</title>
          <description>Subjects will be asked to rate anxiety and pain 30 minutes post-operatively by marking along a mm Visual Analog Scale, with 0mm being No Pain/Anxiety and 100mm being Worst Imaginable Pain/Anxiety</description>
          <population>1 subject in the placebo group did not complete the study after changing mind to have abortion. Baseline information and characteristics on that subject was still collected and included where applicable in study outcomes and data.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anxiety Post Procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.9" spread="22.6"/>
                    <measurement group_id="O2" value="14.4" spread="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain Post Procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.7" spread="23.3"/>
                    <measurement group_id="O2" value="37.1" spread="24.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Perception of Anxiety With Patient Positioning Procedure</title>
        <description>Subjects will be asked to rate anxiety prior to starting pelvic exam by marking along a mm Visual Analog Scale, with 0mm being No Anxiety and 100mm being Worst Imaginable Anxiety</description>
        <time_frame>prior to starting pelvic exam (30-60 minutes after premedication)</time_frame>
        <population>1 subject in the placebo group did not complete the study after changing mind to have abortion. Baseline information and characteristics on that subject was still collected and included where applicable in study outcomes and data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo-cherry Syrup and Ibuprofen</title>
            <description>5 mL oral placebo-cherry syrup and 800 mg oral ibuprofen 30-60 minutes prior to procedure 20 mL injection 1% lidocaine without epinephrine
Ibuprofen: 800 mg oral ibuprofen 30-60 minutes prior to procedure
Placebo-Cherry syrup: 5 mL oral placebo-cherry syrup 30-60 minutes prior to procedure
Lidocaine: injection of 20 mL 1% lidocaine without epinephrine</description>
          </group>
          <group group_id="O2">
            <title>Midazolam and Ibuprofen</title>
            <description>5 mL oral midazolam oral syrup (2 mg/mL) and 800 mg oral ibuprofen 30-60 minutes prior to procedure 20 mL injection 1% lidocaine without epinephrine
Midazolam: 5 mL oral midazolam oral syrup (2 mg/mL) 30-60 minutes prior to procedure
Ibuprofen: 800 mg oral ibuprofen 30-60 minutes prior to procedure
Lidocaine: injection of 20 mL 1% lidocaine without epinephrine</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Perception of Anxiety With Patient Positioning Procedure</title>
          <description>Subjects will be asked to rate anxiety prior to starting pelvic exam by marking along a mm Visual Analog Scale, with 0mm being No Anxiety and 100mm being Worst Imaginable Anxiety</description>
          <population>1 subject in the placebo group did not complete the study after changing mind to have abortion. Baseline information and characteristics on that subject was still collected and included where applicable in study outcomes and data.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.6" spread="26.4"/>
                    <measurement group_id="O2" value="45.4" spread="26.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Perception of Pain During Cervical Dilation</title>
        <description>Subjects will be asked to rate pain at the time of cervical dilation by marking along a mm Visual Analog Scale, with 0mm being No Pain and 100mm being Worst Imaginable Pain</description>
        <time_frame>with cervical dilation (30-60 minutes after premedication)</time_frame>
        <population>1 subject in the placebo group did not complete the study after changing mind to have abortion. Baseline information and characteristics on that subject was still collected and included where applicable in study outcomes and data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo-cherry Syrup and Ibuprofen</title>
            <description>5 mL oral placebo-cherry syrup and 800 mg oral ibuprofen 30-60 minutes prior to procedure 20 mL injection 1% lidocaine without epinephrine
Ibuprofen: 800 mg oral ibuprofen 30-60 minutes prior to procedure
Placebo-Cherry syrup: 5 mL oral placebo-cherry syrup 30-60 minutes prior to procedure
Lidocaine: injection of 20 mL 1% lidocaine without epinephrine</description>
          </group>
          <group group_id="O2">
            <title>Midazolam and Ibuprofen</title>
            <description>5 mL oral midazolam oral syrup (2 mg/mL) and 800 mg oral ibuprofen 30-60 minutes prior to procedure 20 mL injection 1% lidocaine without epinephrine
Midazolam: 5 mL oral midazolam oral syrup (2 mg/mL) 30-60 minutes prior to procedure
Ibuprofen: 800 mg oral ibuprofen 30-60 minutes prior to procedure
Lidocaine: injection of 20 mL 1% lidocaine without epinephrine</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Perception of Pain During Cervical Dilation</title>
          <description>Subjects will be asked to rate pain at the time of cervical dilation by marking along a mm Visual Analog Scale, with 0mm being No Pain and 100mm being Worst Imaginable Pain</description>
          <population>1 subject in the placebo group did not complete the study after changing mind to have abortion. Baseline information and characteristics on that subject was still collected and included where applicable in study outcomes and data.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.0" spread="21.2"/>
                    <measurement group_id="O2" value="69.3" spread="19.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlation Coefficient Between State-Trait Anxiety Inventory Form Y-1 and Visual Analog Scale for Anxiety at Baseline</title>
        <description>To measure the Correlation coefficient between the State-Trait Anxiety Inventory (STAI) Form Y-1 and Visual Analog Scale for anxiety.</description>
        <time_frame>Baseline (upon entry into study)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction With Pain and Anxiety 30 Minutes Postoperatively</title>
        <description>To assess whether oral midazolam is associated with differences in overall patient satisfaction with pain and anxiety control and abortion experience at 30 min postoperatively as measured by a mm Visual Analog Scale with 0mm being Not At All Satisfied and 100mm being Very Satisfied</description>
        <time_frame>30 minutes post-operatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo-cherry Syrup and Ibuprofen</title>
            <description>5 mL oral placebo-cherry syrup and 800 mg oral ibuprofen 30-60 minutes prior to procedure 20 mL injection 1% lidocaine without epinephrine
Ibuprofen: 800 mg oral ibuprofen 30-60 minutes prior to procedure
Placebo-Cherry syrup: 5 mL oral placebo-cherry syrup 30-60 minutes prior to procedure
Lidocaine: injection of 20 mL 1% lidocaine without epinephrine</description>
          </group>
          <group group_id="O2">
            <title>Midazolam and Ibuprofen</title>
            <description>5 mL oral midazolam oral syrup (2 mg/mL) and 800 mg oral ibuprofen 30-60 minutes prior to procedure 20 mL injection 1% lidocaine without epinephrine
Midazolam: 5 mL oral midazolam oral syrup (2 mg/mL) 30-60 minutes prior to procedure
Ibuprofen: 800 mg oral ibuprofen 30-60 minutes prior to procedure
Lidocaine: injection of 20 mL 1% lidocaine without epinephrine</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction With Pain and Anxiety 30 Minutes Postoperatively</title>
          <description>To assess whether oral midazolam is associated with differences in overall patient satisfaction with pain and anxiety control and abortion experience at 30 min postoperatively as measured by a mm Visual Analog Scale with 0mm being Not At All Satisfied and 100mm being Very Satisfied</description>
          <units>mm on a 100 mm Visual Analog Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Satisfaction with anxiety control (100-mm VAS)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.1" spread="29.6"/>
                    <measurement group_id="O2" value="68.9" spread="24.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Satisfaction with pain control (100-mm VAS)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.2" spread="30.7"/>
                    <measurement group_id="O2" value="50.0" spread="27.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Satisfaction With Pain and Anxiety 1-3 Days Post Procedure</title>
        <description>To assess whether oral midazolam is associated with differences in overall patient satisfaction with pain and anxiety control and abortion experience at 1-3 days postoperatively as measured by a mm VAS with 0mm being Not At All Satisfied and 100mm being Very Satisfied</description>
        <time_frame>1-3 days post-operatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo-cherry Syrup and Ibuprofen</title>
            <description>5 mL oral placebo-cherry syrup and 800 mg oral ibuprofen 30-60 minutes prior to procedure 20 mL injection 1% lidocaine without epinephrine
Ibuprofen: 800 mg oral ibuprofen 30-60 minutes prior to procedure
Placebo-Cherry syrup: 5 mL oral placebo-cherry syrup 30-60 minutes prior to procedure
Lidocaine: injection of 20 mL 1% lidocaine without epinephrine</description>
          </group>
          <group group_id="O2">
            <title>Midazolam and Ibuprofen</title>
            <description>5 mL oral midazolam oral syrup (2 mg/mL) and 800 mg oral ibuprofen 30-60 minutes prior to procedure 20 mL injection 1% lidocaine without epinephrine
Midazolam: 5 mL oral midazolam oral syrup (2 mg/mL) 30-60 minutes prior to procedure
Ibuprofen: 800 mg oral ibuprofen 30-60 minutes prior to procedure
Lidocaine: injection of 20 mL 1% lidocaine without epinephrine</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Satisfaction With Pain and Anxiety 1-3 Days Post Procedure</title>
          <description>To assess whether oral midazolam is associated with differences in overall patient satisfaction with pain and anxiety control and abortion experience at 1-3 days postoperatively as measured by a mm VAS with 0mm being Not At All Satisfied and 100mm being Very Satisfied</description>
          <units>mm on a 100 mm Visual Analog Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Satisfaction with anxiety control (100-mm VAS)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.2" spread="31.7"/>
                    <measurement group_id="O2" value="64.7" spread="28.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Satisfaction with pain control (100-mm VAS)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.6" spread="30.8"/>
                    <measurement group_id="O2" value="48.2" spread="30.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Extent of Amnesia Using Amnesia Score</title>
        <description>To assess the extent of amnesia 30 min postoperatively as measured by ability to recall procedure using 4-point scale (0 = unable to recall any proportion of the procedure, 1 = able to recall and describe some portions of the procedure, but overall has minimal recall of the procedure, 2 = able to recall and describe most of the procedure, but admits to inability to recall some portion of the procedure, 3 = able to recall and describe the entire procedure).</description>
        <time_frame>30 minutes postoperatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo-cherry Syrup and Ibuprofen</title>
            <description>5 mL oral placebo-cherry syrup and 800 mg oral ibuprofen 30-60 minutes prior to procedure 20 mL injection 1% lidocaine without epinephrine
Ibuprofen: 800 mg oral ibuprofen 30-60 minutes prior to procedure
Placebo-Cherry syrup: 5 mL oral placebo-cherry syrup 30-60 minutes prior to procedure
Lidocaine: injection of 20 mL 1% lidocaine without epinephrine</description>
          </group>
          <group group_id="O2">
            <title>Midazolam and Ibuprofen</title>
            <description>5 mL oral midazolam oral syrup (2 mg/mL) and 800 mg oral ibuprofen 30-60 minutes prior to procedure 20 mL injection 1% lidocaine without epinephrine
Midazolam: 5 mL oral midazolam oral syrup (2 mg/mL) 30-60 minutes prior to procedure
Ibuprofen: 800 mg oral ibuprofen 30-60 minutes prior to procedure
Lidocaine: injection of 20 mL 1% lidocaine without epinephrine</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Extent of Amnesia Using Amnesia Score</title>
          <description>To assess the extent of amnesia 30 min postoperatively as measured by ability to recall procedure using 4-point scale (0 = unable to recall any proportion of the procedure, 1 = able to recall and describe some portions of the procedure, but overall has minimal recall of the procedure, 2 = able to recall and describe most of the procedure, but admits to inability to recall some portion of the procedure, 3 = able to recall and describe the entire procedure).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Partial to complete amnesia (score 0,1,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Amnesia (score 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Extent of Amnesia</title>
        <description>To assess the extent of amnesia 1-3 days postoperatively as measured by 100mm Visual Analog Scale with 0mm being Remember Nothing and 100mm being Remember Everything.</description>
        <time_frame>1-3 days postoperatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo-cherry Syrup and Ibuprofen</title>
            <description>5 mL oral placebo-cherry syrup and 800 mg oral ibuprofen 30-60 minutes prior to procedure 20 mL injection 1% lidocaine without epinephrine
Ibuprofen: 800 mg oral ibuprofen 30-60 minutes prior to procedure
Placebo-Cherry syrup: 5 mL oral placebo-cherry syrup 30-60 minutes prior to procedure
Lidocaine: injection of 20 mL 1% lidocaine without epinephrine</description>
          </group>
          <group group_id="O2">
            <title>Midazolam and Ibuprofen</title>
            <description>5 mL oral midazolam oral syrup (2 mg/mL) and 800 mg oral ibuprofen 30-60 minutes prior to procedure 20 mL injection 1% lidocaine without epinephrine
Midazolam: 5 mL oral midazolam oral syrup (2 mg/mL) 30-60 minutes prior to procedure
Ibuprofen: 800 mg oral ibuprofen 30-60 minutes prior to procedure
Lidocaine: injection of 20 mL 1% lidocaine without epinephrine</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Extent of Amnesia</title>
          <description>To assess the extent of amnesia 1-3 days postoperatively as measured by 100mm Visual Analog Scale with 0mm being Remember Nothing and 100mm being Remember Everything.</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.5" spread="12.8"/>
                    <measurement group_id="O2" value="61.3" spread="25.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Extent of Sedation</title>
        <description>Subject extent of sedation 30-60 minutes after premedication, just prior to procedure as measured by the 6-point Ramsay Scale (1 = patient anxious agitated, or restless; 2 = patient cooperative, oriented, and tranquil; 3 = patient asleep, responds to commands only; 4 = patient asleep, responds to gentle shaking, light glabellar tap, or loud auditory stimulus; 5 = patient asleep, responds to noxious stimuli such as firm nail bed pressure; 6 = patient asleep, has no response to firm nail bed pressure or other noxious stimuli)</description>
        <time_frame>3-60 minutes after premedication</time_frame>
        <population>1 subject in the placebo group did not complete the study after changing mind to have abortion. Baseline information and characteristics on that subject was still collected and included where applicable in study outcomes and data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo-cherry Syrup and Ibuprofen</title>
            <description>5 mL oral placebo-cherry syrup and 800 mg oral ibuprofen 30-60 minutes prior to procedure 20 mL injection 1% lidocaine without epinephrine
Ibuprofen: 800 mg oral ibuprofen 30-60 minutes prior to procedure
Placebo-Cherry syrup: 5 mL oral placebo-cherry syrup 30-60 minutes prior to procedure
Lidocaine: injection of 20 mL 1% lidocaine without epinephrine</description>
          </group>
          <group group_id="O2">
            <title>Midazolam and Ibuprofen</title>
            <description>5 mL oral midazolam oral syrup (2 mg/mL) and 800 mg oral ibuprofen 30-60 minutes prior to procedure 20 mL injection 1% lidocaine without epinephrine
Midazolam: 5 mL oral midazolam oral syrup (2 mg/mL) 30-60 minutes prior to procedure
Ibuprofen: 800 mg oral ibuprofen 30-60 minutes prior to procedure
Lidocaine: injection of 20 mL 1% lidocaine without epinephrine</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Extent of Sedation</title>
          <description>Subject extent of sedation 30-60 minutes after premedication, just prior to procedure as measured by the 6-point Ramsay Scale (1 = patient anxious agitated, or restless; 2 = patient cooperative, oriented, and tranquil; 3 = patient asleep, responds to commands only; 4 = patient asleep, responds to gentle shaking, light glabellar tap, or loud auditory stimulus; 5 = patient asleep, responds to noxious stimuli such as firm nail bed pressure; 6 = patient asleep, has no response to firm nail bed pressure or other noxious stimuli)</description>
          <population>1 subject in the placebo group did not complete the study after changing mind to have abortion. Baseline information and characteristics on that subject was still collected and included where applicable in study outcomes and data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 or greater</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Vital Signs (Heart Rate)</title>
        <description>Subject heart rate will be assessed for the duration of the procedure</description>
        <time_frame>intraoperatively (30-60 minutes after premedication)</time_frame>
        <population>1 subject in the placebo group did not complete the study after changing mind to have abortion. Baseline information and characteristics on that subject was still collected and included where applicable in study outcomes and data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo-cherry Syrup and Ibuprofen</title>
            <description>5 mL oral placebo-cherry syrup and 800 mg oral ibuprofen 30-60 minutes prior to procedure 20 mL injection 1% lidocaine without epinephrine
Ibuprofen: 800 mg oral ibuprofen 30-60 minutes prior to procedure
Placebo-Cherry syrup: 5 mL oral placebo-cherry syrup 30-60 minutes prior to procedure
Lidocaine: injection of 20 mL 1% lidocaine without epinephrine</description>
          </group>
          <group group_id="O2">
            <title>Midazolam and Ibuprofen</title>
            <description>5 mL oral midazolam oral syrup (2 mg/mL) and 800 mg oral ibuprofen 30-60 minutes prior to procedure 20 mL injection 1% lidocaine without epinephrine
Midazolam: 5 mL oral midazolam oral syrup (2 mg/mL) 30-60 minutes prior to procedure
Ibuprofen: 800 mg oral ibuprofen 30-60 minutes prior to procedure
Lidocaine: injection of 20 mL 1% lidocaine without epinephrine</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Vital Signs (Heart Rate)</title>
          <description>Subject heart rate will be assessed for the duration of the procedure</description>
          <population>1 subject in the placebo group did not complete the study after changing mind to have abortion. Baseline information and characteristics on that subject was still collected and included where applicable in study outcomes and data.</population>
          <units>bmp</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80" lower_limit="51" upper_limit="126"/>
                    <measurement group_id="O2" value="78.5" lower_limit="50" upper_limit="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Vital Signs (Heart Rate) 30 Minutes Postprocedure</title>
        <description>Subject vital signs (heart rate) will be assessed 30 minutes postoperatively</description>
        <time_frame>30 minutes postoperatively</time_frame>
        <population>1 subject in the placebo group did not complete the study after changing mind to have abortion. Baseline information and characteristics on that subject was still collected and included where applicable in study outcomes and data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo-cherry Syrup and Ibuprofen</title>
            <description>5 mL oral placebo-cherry syrup and 800 mg oral ibuprofen 30-60 minutes prior to procedure 20 mL injection 1% lidocaine without epinephrine
Ibuprofen: 800 mg oral ibuprofen 30-60 minutes prior to procedure
Placebo-Cherry syrup: 5 mL oral placebo-cherry syrup 30-60 minutes prior to procedure
Lidocaine: injection of 20 mL 1% lidocaine without epinephrine</description>
          </group>
          <group group_id="O2">
            <title>Midazolam and Ibuprofen</title>
            <description>5 mL oral midazolam oral syrup (2 mg/mL) and 800 mg oral ibuprofen 30-60 minutes prior to procedure 20 mL injection 1% lidocaine without epinephrine
Midazolam: 5 mL oral midazolam oral syrup (2 mg/mL) 30-60 minutes prior to procedure
Ibuprofen: 800 mg oral ibuprofen 30-60 minutes prior to procedure
Lidocaine: injection of 20 mL 1% lidocaine without epinephrine</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Vital Signs (Heart Rate) 30 Minutes Postprocedure</title>
          <description>Subject vital signs (heart rate) will be assessed 30 minutes postoperatively</description>
          <population>1 subject in the placebo group did not complete the study after changing mind to have abortion. Baseline information and characteristics on that subject was still collected and included where applicable in study outcomes and data.</population>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.1" spread="12.4"/>
                    <measurement group_id="O2" value="72" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Nausea 30 Minutes Postprocedure</title>
        <description>Subject nausea will be assessed 30 minutes postoperatively using a 100mm Visual Analog Scale with 0mm being None and 100mm being Worst Imaginable</description>
        <time_frame>30 minutes postoperatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo-cherry Syrup and Ibuprofen</title>
            <description>5 mL oral placebo-cherry syrup and 800 mg oral ibuprofen 30-60 minutes prior to procedure 20 mL injection 1% lidocaine without epinephrine
Ibuprofen: 800 mg oral ibuprofen 30-60 minutes prior to procedure
Placebo-Cherry syrup: 5 mL oral placebo-cherry syrup 30-60 minutes prior to procedure
Lidocaine: injection of 20 mL 1% lidocaine without epinephrine</description>
          </group>
          <group group_id="O2">
            <title>Midazolam and Ibuprofen</title>
            <description>5 mL oral midazolam oral syrup (2 mg/mL) and 800 mg oral ibuprofen 30-60 minutes prior to procedure 20 mL injection 1% lidocaine without epinephrine
Midazolam: 5 mL oral midazolam oral syrup (2 mg/mL) 30-60 minutes prior to procedure
Ibuprofen: 800 mg oral ibuprofen 30-60 minutes prior to procedure
Lidocaine: injection of 20 mL 1% lidocaine without epinephrine</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Nausea 30 Minutes Postprocedure</title>
          <description>Subject nausea will be assessed 30 minutes postoperatively using a 100mm Visual Analog Scale with 0mm being None and 100mm being Worst Imaginable</description>
          <units>100-mm visual analog sclae for nausea</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" lower_limit="0" upper_limit="80"/>
                    <measurement group_id="O2" value="3.5" lower_limit="0" upper_limit="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Need for Additional Pain Medication</title>
        <description>Subjects will be assessed for need of additional pain medications during the procedure and postoperatively</description>
        <time_frame>intraoperatively and postoperatively (0-120 minutes after premedication)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject's Correct Identification of Receiving Midazolam or Placebo</title>
        <description>Number of patient's who could correctly determine if they received study drug or placebo when asked</description>
        <time_frame>30 minutes postoperatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo-cherry Syrup and Ibuprofen</title>
            <description>5 mL oral placebo-cherry syrup and 800 mg oral ibuprofen 30-60 minutes prior to procedure 20 mL injection 1% lidocaine without epinephrine
Ibuprofen: 800 mg oral ibuprofen 30-60 minutes prior to procedure
Placebo-Cherry syrup: 5 mL oral placebo-cherry syrup 30-60 minutes prior to procedure
Lidocaine: injection of 20 mL 1% lidocaine without epinephrine</description>
          </group>
          <group group_id="O2">
            <title>Midazolam and Ibuprofen</title>
            <description>5 mL oral midazolam oral syrup (2 mg/mL) and 800 mg oral ibuprofen 30-60 minutes prior to procedure 20 mL injection 1% lidocaine without epinephrine
Midazolam: 5 mL oral midazolam oral syrup (2 mg/mL) 30-60 minutes prior to procedure
Ibuprofen: 800 mg oral ibuprofen 30-60 minutes prior to procedure
Lidocaine: injection of 20 mL 1% lidocaine without epinephrine</description>
          </group>
        </group_list>
        <measure>
          <title>Subject's Correct Identification of Receiving Midazolam or Placebo</title>
          <description>Number of patient's who could correctly determine if they received study drug or placebo when asked</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Vital Signs (Oxygenation Saturation)</title>
        <description>Subject oxygenation status will be assessed for the duration of the procedure</description>
        <time_frame>intraoperatively (30-60 minutes after premedication)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo-cherry Syrup and Ibuprofen</title>
            <description>5 mL oral placebo-cherry syrup and 800 mg oral ibuprofen 30-60 minutes prior to procedure 20 mL injection 1% lidocaine without epinephrine
Ibuprofen: 800 mg oral ibuprofen 30-60 minutes prior to procedure
Placebo-Cherry syrup: 5 mL oral placebo-cherry syrup 30-60 minutes prior to procedure
Lidocaine: injection of 20 mL 1% lidocaine without epinephrine</description>
          </group>
          <group group_id="O2">
            <title>Midazolam and Ibuprofen</title>
            <description>5 mL oral midazolam oral syrup (2 mg/mL) and 800 mg oral ibuprofen 30-60 minutes prior to procedure 20 mL injection 1% lidocaine without epinephrine
Midazolam: 5 mL oral midazolam oral syrup (2 mg/mL) 30-60 minutes prior to procedure
Ibuprofen: 800 mg oral ibuprofen 30-60 minutes prior to procedure
Lidocaine: injection of 20 mL 1% lidocaine without epinephrine</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Vital Signs (Oxygenation Saturation)</title>
          <description>Subject oxygenation status will be assessed for the duration of the procedure</description>
          <units>percent saturation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.3" spread="1.2"/>
                    <measurement group_id="O2" value="98.1" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Vital Signs (Oxygenation Saturation) 30 Minutes Postprocedure</title>
        <description>Subject vital signs (oxygenation saturation) will be assessed 30 minutes postoperatively</description>
        <time_frame>30 minutes postoperatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo-cherry Syrup and Ibuprofen</title>
            <description>5 mL oral placebo-cherry syrup and 800 mg oral ibuprofen 30-60 minutes prior to procedure 20 mL injection 1% lidocaine without epinephrine
Ibuprofen: 800 mg oral ibuprofen 30-60 minutes prior to procedure
Placebo-Cherry syrup: 5 mL oral placebo-cherry syrup 30-60 minutes prior to procedure
Lidocaine: injection of 20 mL 1% lidocaine without epinephrine</description>
          </group>
          <group group_id="O2">
            <title>Midazolam and Ibuprofen</title>
            <description>5 mL oral midazolam oral syrup (2 mg/mL) and 800 mg oral ibuprofen 30-60 minutes prior to procedure 20 mL injection 1% lidocaine without epinephrine
Midazolam: 5 mL oral midazolam oral syrup (2 mg/mL) 30-60 minutes prior to procedure
Ibuprofen: 800 mg oral ibuprofen 30-60 minutes prior to procedure
Lidocaine: injection of 20 mL 1% lidocaine without epinephrine</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Vital Signs (Oxygenation Saturation) 30 Minutes Postprocedure</title>
          <description>Subject vital signs (oxygenation saturation) will be assessed 30 minutes postoperatively</description>
          <units>percent saturation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.3" spread="1.2"/>
                    <measurement group_id="O2" value="98.1" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Sleepiness 30 Minutes Postprocedure</title>
        <description>Subject sleepiness will be assessed 30 minutes postoperatively using a 100mm Visual Analog Scale with 0mm being None and 100mm being Worst Imaginable</description>
        <time_frame>30 minutes postoperatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo-cherry Syrup and Ibuprofen</title>
            <description>5 mL oral placebo-cherry syrup and 800 mg oral ibuprofen 30-60 minutes prior to procedure 20 mL injection 1% lidocaine without epinephrine
Ibuprofen: 800 mg oral ibuprofen 30-60 minutes prior to procedure
Placebo-Cherry syrup: 5 mL oral placebo-cherry syrup 30-60 minutes prior to procedure
Lidocaine: injection of 20 mL 1% lidocaine without epinephrine</description>
          </group>
          <group group_id="O2">
            <title>Midazolam and Ibuprofen</title>
            <description>5 mL oral midazolam oral syrup (2 mg/mL) and 800 mg oral ibuprofen 30-60 minutes prior to procedure 20 mL injection 1% lidocaine without epinephrine
Midazolam: 5 mL oral midazolam oral syrup (2 mg/mL) 30-60 minutes prior to procedure
Ibuprofen: 800 mg oral ibuprofen 30-60 minutes prior to procedure
Lidocaine: injection of 20 mL 1% lidocaine without epinephrine</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Sleepiness 30 Minutes Postprocedure</title>
          <description>Subject sleepiness will be assessed 30 minutes postoperatively using a 100mm Visual Analog Scale with 0mm being None and 100mm being Worst Imaginable</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.1" spread="29.3"/>
                    <measurement group_id="O2" value="56.6" spread="24.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo-cherry Syrup and Ibuprofen</title>
          <description>5 mL oral placebo-cherry syrup and 800 mg oral ibuprofen 30-60 minutes prior to procedure 20 mL injection 1% lidocaine without epinephrine
Ibuprofen: 800 mg oral ibuprofen 30-60 minutes prior to procedure
Placebo-Cherry syrup: 5 mL oral placebo-cherry syrup 30-60 minutes prior to procedure
Lidocaine: injection of 20 mL 1% lidocaine without epinephrine</description>
        </group>
        <group group_id="E2">
          <title>Midazolam and Ibuprofen</title>
          <description>5 mL oral midazolam oral syrup (2 mg/mL) and 800 mg oral ibuprofen 30-60 minutes prior to procedure 20 mL injection 1% lidocaine without epinephrine
Midazolam: 5 mL oral midazolam oral syrup (2 mg/mL) 30-60 minutes prior to procedure
Ibuprofen: 800 mg oral ibuprofen 30-60 minutes prior to procedure
Lidocaine: injection of 20 mL 1% lidocaine without epinephrine</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Reaspiration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Cervical laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Lisa Bayer, MD</name_or_title>
      <organization>Oregon Health and Science University</organization>
      <phone>503-494-3666</phone>
      <email>whru@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

